SPY303.53+4.45 1.49%
DIA255.77+5.52 2.21%
IXIC9,412.36+72.14 0.77%

Morgan Stanley Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $27

Morgan Stanley maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $30 to $27.

Benzinga · 05/11/2020 13:12

Morgan Stanley maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $30 to $27.